PMID- 31276466
OWN - NLM
STAT- MEDLINE
DCOM- 20200107
LR  - 20200309
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Print)
IS  - 1935-2727 (Linking)
VI  - 13
IP  - 7
DP  - 2019 Jul
TI  - Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA 
      class II immunoprevalence.
PG  - e0007547
LID - 10.1371/journal.pntd.0007547 [doi]
LID - e0007547
AB  - BACKGROUND: Efficient adaptive antiviral cellular and humoral immune responses 
      require previous recognition of viral antigenic peptides bound to human leukocyte 
      antigen (HLA) class I and II molecules, which are exposed on the surface of 
      infected and antigen presenting cells, respectively. The HLA-restricted immune 
      response to Chikungunya virus (CHIKV), a mosquito-borne Alphavirus of the 
      Togaviridae family responsible for severe chronic polyarthralgia and 
      polyarthritis, is largely unknown. METHODOLOGY/PRINCIPAL FINDINGS: In this study, 
      a high-throughput mass spectrometry analysis of complex HLA-bound peptide pools 
      isolated from large amounts of human cells infected with a vaccinia virus (VACV) 
      recombinant expressing CHIKV structural proteins was carried out. Twelve viral 
      ligands from the CHIKV polyprotein naturally presented by different HLA-A, -B, 
      and -C class I, and HLA-DR and -DP class II molecules were identified. 
      CONCLUSIONS/SIGNIFICANCE: The immunoprevalence of the HLA class II but not the 
      HLA class I-restricted cellular immune response against the CHIKV structural 
      polyprotein was greater than that against the VACV vector itself. In addition, 
      most of the CHIKV HLA class I and II ligands detected by mass spectrometry are 
      not conserved compared to its closely related O'nyong-nyong virus. These findings 
      have clear implications for analysis of both cytotoxic and helper immune 
      responses against CHIKV as well as for the future studies focused in the 
      exacerbated T helper response linked to chronic musculoskeletal disorders in 
      CHIKV patients.
FAU - Lorente, Elena
AU  - Lorente E
AD  - Unidad de Presentacion y Regulacion Inmunes, Centro Nacional de Microbiologia, 
      Instituto de Salud Carlos III, Majadahonda (Madrid), Spain.
FAU - Barriga, Alejandro
AU  - Barriga A
AD  - Unidad de Presentacion y Regulacion Inmunes, Centro Nacional de Microbiologia, 
      Instituto de Salud Carlos III, Majadahonda (Madrid), Spain.
FAU - Barnea, Eilon
AU  - Barnea E
AD  - Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
FAU - Palomo, Concepcion
AU  - Palomo C
AD  - Unidad de Presentacion y Regulacion Inmunes, Centro Nacional de Microbiologia, 
      Instituto de Salud Carlos III, Majadahonda (Madrid), Spain.
FAU - Garcia-Arriaza, Juan
AU  - Garcia-Arriaza J
AD  - Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, 
      Consejo Superior de Investigaciones Cientificas (CSIC), Madrid, Spain.
FAU - Mir, Carmen
AU  - Mir C
AD  - Unidad de Presentacion y Regulacion Inmunes, Centro Nacional de Microbiologia, 
      Instituto de Salud Carlos III, Majadahonda (Madrid), Spain.
FAU - Esteban, Mariano
AU  - Esteban M
AD  - Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, 
      Consejo Superior de Investigaciones Cientificas (CSIC), Madrid, Spain.
FAU - Admon, Arie
AU  - Admon A
AD  - Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
FAU - Lopez, Daniel
AU  - Lopez D
AUID- ORCID: 0000-0003-0268-5878
AD  - Unidad de Presentacion y Regulacion Inmunes, Centro Nacional de Microbiologia, 
      Instituto de Salud Carlos III, Majadahonda (Madrid), Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190705
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Viral Proteins)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Antigen Presentation
MH  - Antigen-Presenting Cells/immunology
MH  - Chikungunya Fever/immunology/*prevention & control
MH  - Chikungunya virus
MH  - Histocompatibility Antigens Class II/*immunology
MH  - Humans
MH  - Immunity, Cellular
MH  - Immunogenicity, Vaccine
MH  - Mass Spectrometry
MH  - Mice
MH  - *Proteomics
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - T-Lymphocytes, Helper-Inducer/immunology
MH  - *Vaccinia virus
MH  - Viral Proteins/*immunology
MH  - Viral Vaccines/genetics/*immunology
PMC - PMC6636782
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/07/06 06:00
MHDA- 2020/01/08 06:00
PMCR- 2019/07/05
CRDT- 2019/07/06 06:00
PHST- 2019/02/06 00:00 [received]
PHST- 2019/06/11 00:00 [accepted]
PHST- 2019/07/17 00:00 [revised]
PHST- 2019/07/06 06:00 [pubmed]
PHST- 2020/01/08 06:00 [medline]
PHST- 2019/07/06 06:00 [entrez]
PHST- 2019/07/05 00:00 [pmc-release]
AID - PNTD-D-19-00186 [pii]
AID - 10.1371/journal.pntd.0007547 [doi]
PST - epublish
SO  - PLoS Negl Trop Dis. 2019 Jul 5;13(7):e0007547. doi: 10.1371/journal.pntd.0007547. 
      eCollection 2019 Jul.